Search research articles
Contact Us
Filters
Showing results (271-280 of 347) with videos related to
Page
of 35
Sort By:
European Journal of Haematology
|
November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial
Tim Richardson, Elias Mai, Ekaterina Menis, et al.
Hemasphere
|
January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
International Journal of Cancer
|
September 19, 2022
Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial
Agne Krilaviciute, Peter Albers, Jale Lakes, et al.
Blood Cancer Journal
|
January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Katharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Acta Neuropathologica
|
August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
Till Milde, Susanne Kleber, Andrey Korshunov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma
Elke Pfaff, Marc Remke, Dominik Sturm, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 22, 2019
Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer
Mariam Haffa, Andreana N Holowatyj, Mario Kratz, et al.
Leukemia
|
February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myeloma
Mohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Blood
|
January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Dirk Hose, Thierry Rème, Tobias Meissner, et al.
European Journal of Immunology
|
February 4, 2009
DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands
Caroline End, Floris Bikker, Marcus Renner, et al.
Page
of 35
Search research articles
Search
Showing results (271-280 of 347) with videos related to
Sort By:
Page
of 35
European Journal of Haematology
|
November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial
Tim Richardson, Elias Mai, Ekaterina Menis, et al.
Hemasphere
|
January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
International Journal of Cancer
|
September 19, 2022
Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial
Agne Krilaviciute, Peter Albers, Jale Lakes, et al.
Blood Cancer Journal
|
January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Katharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Acta Neuropathologica
|
August 25, 2011
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat
Till Milde, Susanne Kleber, Andrey Korshunov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma
Elke Pfaff, Marc Remke, Dominik Sturm, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 22, 2019
Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer
Mariam Haffa, Andreana N Holowatyj, Mario Kratz, et al.
Leukemia
|
February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myeloma
Mohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
Blood
|
January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Dirk Hose, Thierry Rème, Tobias Meissner, et al.
European Journal of Immunology
|
February 4, 2009
DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands
Caroline End, Floris Bikker, Marcus Renner, et al.
Page
of 35